Patents by Inventor Zizheng Zheng

Zizheng Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY FOR RECOGNIZING RSV PRE-F PROTEIN AND USE THEREOF
    Publication number: 20240409621
    Abstract: The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and/or treatment of RSV infection and/or diseases caused by the infections.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 12, 2024
    Applicant: XIAMEN UNIVERSITY
    Inventors: Zizheng ZHENG, Yongpeng SUN, Siyu LEI, Hongsheng QIANG, Li CHEN, Ningshao XIA
  • METHODS FOR INACTIVATING AND STORING RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20220009969
    Abstract: Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 13, 2022
    Applicants: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Zizheng Zheng, Wei Zhang, Lujing Zhang, Yongpeng Sun, Li Chen, Ningshao Xia
  • Epitope of RSV fusion protein and antibody recognizing the same
    Patent number: 9856313
    Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 2, 2018
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
  • EPITOPE OF RSV FUSION PROTEIN AND ANTIBODY RECOGNIZING THE SAME
    Publication number: 20160031972
    Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITY
    Inventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia